WO2000069269A1 - Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium - Google Patents
Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium Download PDFInfo
- Publication number
- WO2000069269A1 WO2000069269A1 PCT/US2000/006718 US0006718W WO0069269A1 WO 2000069269 A1 WO2000069269 A1 WO 2000069269A1 US 0006718 W US0006718 W US 0006718W WO 0069269 A1 WO0069269 A1 WO 0069269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phage
- enterococcus faecium
- vancomycin
- enb6
- pta
- Prior art date
Links
- 108010059993 Vancomycin Proteins 0.000 title claims abstract description 13
- 229960003165 vancomycin Drugs 0.000 title claims abstract description 13
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title claims abstract description 13
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 title claims abstract description 13
- 241000194031 Enterococcus faecium Species 0.000 title claims abstract description 12
- 241001515965 unidentified phage Species 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 16
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000007922 nasal spray Substances 0.000 claims description 3
- 229940097496 nasal spray Drugs 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims description 2
- 206010014889 Enterococcal infections Diseases 0.000 claims 3
- 241000792859 Enema Species 0.000 claims 2
- 239000007920 enema Substances 0.000 claims 2
- 229940095399 enema Drugs 0.000 claims 2
- 230000002262 irrigation Effects 0.000 claims 2
- 238000003973 irrigation Methods 0.000 claims 2
- 239000000829 suppository Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 20
- 208000031729 Bacteremia Diseases 0.000 abstract description 11
- 230000001580 bacterial effect Effects 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 3
- 230000001018 virulence Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010024264 Lethargy Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- PPKJUHVNTMYXOD-PZGPJMECSA-N c49ws9n75l Chemical compound O=C([C@@H]1N(C2=O)CC[C@H]1S(=O)(=O)CCN(CC)CC)O[C@H](C(C)C)[C@H](C)\C=C\C(=O)NC\C=C\C(\C)=C\[C@@H](O)CC(=O)CC1=NC2=CO1.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2C[C@@H](CS[C@H]3C4CCN(CC4)C3)C(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O PPKJUHVNTMYXOD-PZGPJMECSA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 238000001066 phage therapy Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 108010071077 quinupristin-dalfopristin Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940020707 synercid Drugs 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10311—Siphoviridae
- C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Definitions
- MDR Enterococcus faecium
- MDR multidrug resistant
- Synercid® recently entered the market as a treatment for vancomycin-resistant bacteria, including VREF.
- MDR bacteria are so efficient at resisting newer antibiotics (even those to which
- efflux pump can transport out many classes of drugs; and a mutation in the
- ribosomal subunit targeted by antibiotics can defeat several classes of drugs.
- Bacte ophage (phage) therapy offers one such alternative.
- phage strains for example ENB6
- phages tend to be rapidly cleared from the systemic circulation by the filtering action
- the technique also selects for those mutants that retain their ability to lyse the target
- phage stains that attack VREF hosts have
- Phage strains were grown by standard techniques known in the art,
- the ENB6 genome contains at least 120 kb of DNA as determined by
- nucleotide sequence has been defined at 99% confidence, while 24.7 kb has been defined at a lower level of confidence. The remaining amount is presently
- ENB6 nucleotide sequences have been compared to all genes and
- Figure 2 is an electron microscopic picture of phage ENB6.
- the routes of administration include but are not limited to: oral, aerosol or
- intrathecal intraperitoneal, intrathecal, vaginal, rectal, topical, lumbar puncture, intrathecal,
- the free phage could be in lyophilized form and be
- administration is contemplated to be in the range of about 10 3 to about 10 13
- the phage are Table 2. Proteins screened by PCR amplification of ENB6 DNA.
- the present invention will be particularly useful in treating critically ill
- ENB6 ATCC # PTA-40
- ENB13 ATCC # PTA-39
- Figures 3 and 4 show the results of a dose-finding study.
- CRMEN44 is 1 x 10 9 CFU, when injected I. P. into one month-old balb/c
- PFU plaque forming units PFU
- the non-parametric rating scale for observable signs of illness is as follows:
- Phage administered as a control did not produce any detectable symptoms in the
- Phage ENB6 rescues animals from an otherwise-fatal dose of VREF, a bacterial
- Figures 5 and 6 show the results of delay in the treatment of a fulminant
- VREF are orders-of-magnitude lower than the concentrations achieved here, so it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU49719/00A AU4971900A (en) | 1999-05-13 | 2000-05-12 | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
JP2000617737A JP2002543816A (en) | 1999-05-13 | 2000-05-12 | Bacteriophage strains useful to rescue patients infected with vancomycin-resistant enterococcal strains |
CA002373486A CA2373486A1 (en) | 1999-05-13 | 2000-05-12 | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
EP00931911A EP1180937A4 (en) | 1999-05-13 | 2000-05-12 | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13405599P | 1999-05-13 | 1999-05-13 | |
US60/134,055 | 1999-05-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000069269A1 true WO2000069269A1 (en) | 2000-11-23 |
WO2000069269A9 WO2000069269A9 (en) | 2002-02-21 |
Family
ID=22461568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/006718 WO2000069269A1 (en) | 1999-05-13 | 2000-05-12 | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1180937A4 (en) |
JP (1) | JP2002543816A (en) |
AU (1) | AU4971900A (en) |
CA (1) | CA2373486A1 (en) |
WO (1) | WO2000069269A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051066A2 (en) * | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Reduction in bacterial colonization by administering bacteriophage compositions |
US6759229B2 (en) | 2001-12-18 | 2004-07-06 | President & Fellows Of Harvard College | Toxin-phage bacteriocide antibiotic and uses thereof |
WO2005028017A1 (en) * | 2003-09-10 | 2005-03-31 | Wilhelm Fleischmann | Device and method for applying active substances to the surface of a wound |
JP2005523943A (en) * | 2002-04-27 | 2005-08-11 | ユニヴァーシティー オヴ ストラスクライド | Virus immobilization and stabilization |
US7588929B2 (en) | 2002-12-09 | 2009-09-15 | Phage Biopharm Llc | Production of bacteriophage compositions for use in phage therapy |
WO2010036132A1 (en) | 2008-09-29 | 2010-04-01 | Instytut Immunologii i Terapii Doświadczalnej PAN | Novel bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus enterococcus |
KR100958139B1 (en) * | 2008-03-31 | 2010-05-18 | 주식회사 인트론바이오테크놀로지 | Novel Bacteriophage Having Killing Activity Specific to Enterococcus faecalis |
KR100988771B1 (en) * | 2008-09-29 | 2010-10-20 | 주식회사 인트론바이오테크놀로지 | Novel Lysin Protein Having Killing Activity Specific to Enterococcus and Streptococcus |
WO2010090542A3 (en) * | 2009-02-06 | 2010-12-23 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibacterial phage, phage peptides and methods of use thereof |
US8178087B2 (en) | 2006-04-04 | 2012-05-15 | Centre National de la Recherche Scientifique —CNRS | Process of production of bacteriophage compositions and methods in phage therapy field |
WO2017177196A1 (en) | 2016-04-08 | 2017-10-12 | The Trustees Of Princeton University | Novel antimicrobial compositions and methods of use |
KR20180096921A (en) * | 2017-02-22 | 2018-08-30 | 주식회사 인트론바이오테크놀로지 | Novel antibacterial protein EFAL-2 having lytic activity against Enterococcus faecium |
WO2018155812A1 (en) * | 2017-02-22 | 2018-08-30 | 주식회사 인트론바이오테크놀로지 | Novel enterococcus faecium bacteriophage ent-fap-4 and use for inhibiting enterococcus faecium proliferation of same |
WO2019030257A1 (en) | 2017-08-08 | 2019-02-14 | Snipr Technologies Limited | Propagator cells and methods for propagating phage, in particular for delivering crispr-cas components via probiotic organisms |
KR20200080162A (en) * | 2018-12-26 | 2020-07-06 | 주식회사 옵티팜 | Novel Enterococcus faecium specific bacteriophage EF44 and antibacterial composition comprising the same |
WO2020152369A1 (en) | 2019-01-27 | 2020-07-30 | Snipr Biome Aps | Methods, uses & compositions |
WO2022264035A1 (en) * | 2021-06-15 | 2022-12-22 | Ferring B.V. | Bacteriophages against vancomycin-resistant enterococci |
WO2024003301A1 (en) | 2022-06-29 | 2024-01-04 | Snipr Biome Aps | Targeting e coli cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688501A (en) * | 1994-04-05 | 1997-11-18 | Exponential Biotherapies, Inc. | Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system |
-
2000
- 2000-05-12 WO PCT/US2000/006718 patent/WO2000069269A1/en not_active Application Discontinuation
- 2000-05-12 EP EP00931911A patent/EP1180937A4/en not_active Withdrawn
- 2000-05-12 AU AU49719/00A patent/AU4971900A/en not_active Abandoned
- 2000-05-12 JP JP2000617737A patent/JP2002543816A/en active Pending
- 2000-05-12 CA CA002373486A patent/CA2373486A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5688501A (en) * | 1994-04-05 | 1997-11-18 | Exponential Biotherapies, Inc. | Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7459272B2 (en) | 2000-01-11 | 2008-12-02 | Intralytix, Inc. | Reduction in bacterial colonization by administering bacteriophage compositions |
WO2001051066A3 (en) * | 2000-01-11 | 2002-01-10 | Intralytix Inc | Reduction in bacterial colonization by administering bacteriophage compositions |
US6699701B1 (en) | 2000-01-11 | 2004-03-02 | Intralytix, Inc. | Method and device for sanitation using bacteriophages |
US8003323B2 (en) | 2000-01-11 | 2011-08-23 | Intralytix, Inc. | Reduction in bacterial colonization by administering bacteriophage compositions |
WO2001051066A2 (en) * | 2000-01-11 | 2001-07-19 | Intralytix, Inc. | Reduction in bacterial colonization by administering bacteriophage compositions |
US6759229B2 (en) | 2001-12-18 | 2004-07-06 | President & Fellows Of Harvard College | Toxin-phage bacteriocide antibiotic and uses thereof |
JP2005523943A (en) * | 2002-04-27 | 2005-08-11 | ユニヴァーシティー オヴ ストラスクライド | Virus immobilization and stabilization |
JP2012211135A (en) * | 2002-04-27 | 2012-11-01 | Univ Of Strathclyde | Immobilization and stabilization of virus |
US7588929B2 (en) | 2002-12-09 | 2009-09-15 | Phage Biopharm Llc | Production of bacteriophage compositions for use in phage therapy |
WO2005028017A1 (en) * | 2003-09-10 | 2005-03-31 | Wilhelm Fleischmann | Device and method for applying active substances to the surface of a wound |
US8178087B2 (en) | 2006-04-04 | 2012-05-15 | Centre National de la Recherche Scientifique —CNRS | Process of production of bacteriophage compositions and methods in phage therapy field |
KR100958139B1 (en) * | 2008-03-31 | 2010-05-18 | 주식회사 인트론바이오테크놀로지 | Novel Bacteriophage Having Killing Activity Specific to Enterococcus faecalis |
WO2010036132A1 (en) | 2008-09-29 | 2010-04-01 | Instytut Immunologii i Terapii Doświadczalnej PAN | Novel bacteriophage strains for the treatment of bacterial infections, especially drug resistant strains of the genus enterococcus |
KR100988771B1 (en) * | 2008-09-29 | 2010-10-20 | 주식회사 인트론바이오테크놀로지 | Novel Lysin Protein Having Killing Activity Specific to Enterococcus and Streptococcus |
AU2010211456B2 (en) * | 2009-02-06 | 2016-05-26 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
CN105456300B (en) * | 2009-02-06 | 2019-07-09 | 抗菌技术,生物技术研究与发展股份有限公司 | Antibacterial bacteriophage, phage display peptide and its application method |
JP2015154771A (en) * | 2009-02-06 | 2015-08-27 | テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー | Antibacterial phages, phage peptides and use methods thereof |
US9134312B2 (en) | 2009-02-06 | 2015-09-15 | Tecnifar—Industria Tecnica Farmaceutica, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
CN105456300A (en) * | 2009-02-06 | 2016-04-06 | 抗菌技术,生物技术研究与发展股份有限公司 | Antibacterial phage, phage peptides and methods of use thereof |
RU2580248C2 (en) * | 2009-02-06 | 2016-04-10 | Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са | Bacteriophage possessing anti-pseudomonas aeruginosa activity, bacteriophage proteins and methods for using them |
WO2010090542A3 (en) * | 2009-02-06 | 2010-12-23 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Antibacterial phage, phage peptides and methods of use thereof |
EP3115054A1 (en) * | 2009-02-06 | 2017-01-11 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Antibacterial phage, phage peptides and methods of use thereof |
US9682110B2 (en) | 2009-02-06 | 2017-06-20 | Technophage, Investigação E Desenvolvimento Em Biotechnologia, SA | Antibacterial phage, phage peptides and methods of use thereof |
JP2017158568A (en) * | 2009-02-06 | 2017-09-14 | テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー | Antibiotic phages, phage peptides, and methods of use thereof |
RU2580248C9 (en) * | 2009-02-06 | 2018-01-17 | Текнофахе, Инвестигасао Э Десенвольвименто Эм Биотекнолохия, Са | Bacteriophage possessing anti-pseudomonas aeruginosa activity, bacteriophage proteins and methods for using them |
JP2012517225A (en) * | 2009-02-06 | 2012-08-02 | テクノファージ, インベスティガサン エ デセンボルビメント エム ビオテクノロジア,エスエー | Antibacterial phage, phage peptide, and methods of use thereof |
WO2017177196A1 (en) | 2016-04-08 | 2017-10-12 | The Trustees Of Princeton University | Novel antimicrobial compositions and methods of use |
EP3587565A4 (en) * | 2017-02-22 | 2020-12-02 | Intron Biotechnology, Inc. | Novel enterococcus faecium bacteriophage ent-fap-4 and use for inhibiting enterococcus faecium proliferation of same |
US11458177B2 (en) | 2017-02-22 | 2022-10-04 | Intron Biotechnology, Inc. | Enterococcus faecium bacteriophage Ent-FAP-4 and use for inhibiting Enterococcus faecium proliferation of same |
KR101957266B1 (en) | 2017-02-22 | 2019-03-13 | 주식회사 인트론바이오테크놀로지 | Novel antibacterial protein EFAL-2 having lytic activity against Enterococcus faecium |
WO2018155812A1 (en) * | 2017-02-22 | 2018-08-30 | 주식회사 인트론바이오테크놀로지 | Novel enterococcus faecium bacteriophage ent-fap-4 and use for inhibiting enterococcus faecium proliferation of same |
CN110621776A (en) * | 2017-02-22 | 2019-12-27 | 尹特荣生物科技株式会社 | Novel enterococcus faecium phage end-FAP-4 and application thereof in inhibiting proliferation of enterococcus faecium |
CN110621690A (en) * | 2017-02-22 | 2019-12-27 | 尹特荣生物科技株式会社 | Novel antibacterial protein EFAL-2 having bacteriolytic ability against enterococcus faecium |
WO2018155813A3 (en) * | 2017-02-22 | 2019-01-10 | 주식회사 인트론바이오테크놀로지 | Novel antibacterial protein efal-2 having bacteriolytic ability with respect to enterococcus faecium |
KR20180096921A (en) * | 2017-02-22 | 2018-08-30 | 주식회사 인트론바이오테크놀로지 | Novel antibacterial protein EFAL-2 having lytic activity against Enterococcus faecium |
US11492378B2 (en) | 2017-02-22 | 2022-11-08 | Intron Biotechnology, Inc. | Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium |
WO2019030257A1 (en) | 2017-08-08 | 2019-02-14 | Snipr Technologies Limited | Propagator cells and methods for propagating phage, in particular for delivering crispr-cas components via probiotic organisms |
US11891629B2 (en) | 2017-08-08 | 2024-02-06 | Snipr Technologies Limited | Propagator cells and methods for propagating phage, in particular for delivering CRISPR-Cas components via probiotic organisms |
KR20200080162A (en) * | 2018-12-26 | 2020-07-06 | 주식회사 옵티팜 | Novel Enterococcus faecium specific bacteriophage EF44 and antibacterial composition comprising the same |
KR102203679B1 (en) | 2018-12-26 | 2021-01-15 | 주식회사 옵티팜 | Novel Enterococcus faecium specific bacteriophage EF44 and antibacterial composition comprising the same |
WO2020152369A1 (en) | 2019-01-27 | 2020-07-30 | Snipr Biome Aps | Methods, uses & compositions |
WO2022264035A1 (en) * | 2021-06-15 | 2022-12-22 | Ferring B.V. | Bacteriophages against vancomycin-resistant enterococci |
WO2024003301A1 (en) | 2022-06-29 | 2024-01-04 | Snipr Biome Aps | Targeting e coli cells |
Also Published As
Publication number | Publication date |
---|---|
JP2002543816A (en) | 2002-12-24 |
AU4971900A (en) | 2000-12-05 |
CA2373486A1 (en) | 2000-11-23 |
EP1180937A1 (en) | 2002-02-27 |
WO2000069269A9 (en) | 2002-02-21 |
EP1180937A4 (en) | 2004-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000069269A1 (en) | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium | |
Nishikawa et al. | T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections | |
US5811093A (en) | Bacteriophage genotypically modified to delay inactivations by the host defense system | |
US11492378B2 (en) | Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium | |
JP7449967B2 (en) | therapeutic bacteriophage composition | |
CN112218659A (en) | Therapeutic phage compositions for the treatment of staphylococcal infections | |
US20010043924A1 (en) | Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system | |
AU2004200450B2 (en) | Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium | |
WO2004020635A1 (en) | Bacteriophages and remedies for bacterial infection | |
KR102510118B1 (en) | Bacteriophage CAP-1 with growth inhibition activity against Cutibacterium acnes | |
CN115038799A (en) | Methods of treating bacterial infections | |
WO2019191508A1 (en) | Biomarker and treatment target for alcoholic hepatitis | |
US20240189373A1 (en) | Bacteriophage compositions for treating staphylococcus infection | |
US20230092021A1 (en) | Bacteriophage compositions for treating staphylococcus infection | |
EP3442551B1 (en) | A bacteriophage strain capable of producing a lytic infection in the escherichia coli st131-o25b:h4 clone | |
EP3440200B1 (en) | Modified bacteriophage | |
CN115725607A (en) | Pathogenic target gene of nocardia meliloti and application thereof | |
WO2023288334A1 (en) | Method of treating drug resistant eskape pathogens using therapeutic bacteriophages | |
KR20230159558A (en) | Compositions and methods for inhibiting the growth of enterotoxigenic Bacteroides fragilis | |
Sahni | Review on Phage Therapy | |
Godány et al. | Phage therapy: Alternative approach to antibiotics | |
Lin et al. | Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2373486 Country of ref document: CA Ref country code: CA Ref document number: 2373486 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 617737 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 515506 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49719/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000931911 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09926514 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1-13, DESCRIPTION, REPLACED BY NEW PAGES 1-13; PAGES 14-16, CLAIMS, REPLACED BY NEW PAGES 14-16; PAGES 1/7-7/7, DRAWINGS, REPLACED BY NEW PAGES 1/12-12/12; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931911 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931911 Country of ref document: EP |